Patents Assigned to The United States of America, as represented by the Secretary of the Army, on behalf of the United
  • THERAPEUTIC COMPOSITIONS FOR NEUTRALIZING TYPE I INTERFERONS, AND METHODS OF USE
    Publication number: 20180110826
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Application
    Filed: December 1, 2017
    Publication date: April 26, 2018
    Applicant: The United States of America, as represented by the Secretary of the Army, on behalf of the United
    Inventors: JOSEPH GOLDEN, JAY HOOPER
  • Therapeutic compositions for neutralizing type I interferons, and methods of use
    Patent number: 9861681
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: January 9, 2018
    Assignee: The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases
    Inventors: Joseph Golden, Jay Hooper
  • ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF USE
    Publication number: 20150337015
    Abstract: The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus.
    Type: Application
    Filed: June 4, 2015
    Publication date: November 26, 2015
    Applicant: The United States of America, as represented by the Secretary of the Army, on behalf of the United
    Inventors: CONNIE SCHMALJOHN, Robert F. Garry, Jeffrey W. Koehler, Mary Guttieri